Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  American Journal of Cardiology

• Publication date

  2011-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.amjcard.2010.11.026PMID 21256465
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials.

  2010cited by this paper
• Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention.

  2010cited by this paper
• Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor

  2009cited by this paper
• Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy

  2009cited by this paper
• Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial.

  2008cited by this paper
• Effect of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial: The Telmisartan Randomised Assessment Study in ACE intolerant subjects with cardiovascular Disease (TRANSCEND)

  2008cited by this paper
• Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.

  2008cited by this paper
• Telmisartan, ramipril, or both in patients at high risk for vascular events.

  2008cited by this paper
• 2007 Guidelines for the management of arterial hypertension

  2007cited by this paper
• 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)

  2007cited by this paper
• Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine

  2006cited by this paper
• Angiotensin receptors: a new role in cancer?

  2005cited by this paper
• Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer.

  2004cited by this paper
• Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

  2004cited by this paper
• Angiotensin converting enzyme inhibitors for cancer treatment?

  2004cited by this paper
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.

  2003cited by this paper
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

  2003cited by this paper
• Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

  2003cited by this paper
• Old antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists.

  2002cited by this paper
• Angiotensin II Type 1 Receptor Blockers

  2001cited by this paper
• Angiotensin-converting enzyme inhibitors and risk of cancer - A population-based cohort study in Denmark

  2001cited by this paper
• Angiotensin‐converting enzyme inhibitors and the risk of cancer

  2001cited by this paper
• Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

  2000cited by this paper
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

  2000cited by this paper
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

  2000cited by this paper
• Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients

  2000cited by this paper
• Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group.

  2000cited by this paper
• Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma.

  1998cited by this paper
• Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?

  1998cited by this paper
• Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats.

  1996cited by this paper
• Racial difference in incidence of cough with angiotensin-converting enzyme inhibitors (a tale of two cities).

  1995cited by this paper
• Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

  1991cited by this paper
• Induction of angiogenesis during the transition from hyperplasia to neoplasia

  1989cited by this paper

• Potential blood pressure regulatory effect of low molecular weight α-chymotrypsin extract and its peptides from Stichopus japonicus: Peptide-ACE interaction study via in silico molecular docking

  2024cites this paper
• Angiotensin Receptor Blocker Associated with a Decreased Risk of Lung Cancer: An Updated Meta-Analysis

  2023influential citation
• Cancer Metastasis and Treatment Resistance: Mechanistic Insights and Therapeutic Targeting of Cancer Stem Cells and the Tumor Microenvironment

  2022cites this paper
• Antihypertensive Drugs and the Risk of Cancer: A Nationwide Cohort Study

  2021cites this paper
• Association Between Antihypertensive Medication Use and Breast Cancer: A Systematic Review and Meta-Analysis

  2021cites this paper
• Angiotensin II receptor blockers and oral squamous cell carcinoma survival: A propensity-score-matched cohort study

  2021cites this paper
• Angiotensin II Receptor Blockers Improve Survival in Patients With Locally Advanced Oral Squamous Cell Carcinoma- A Propensity-Score-Matched Study

  2021cites this paper
• Subclinical cardiac damage in cancer patients before chemotherapy

  2021cites this paper
• Angiotensin II receptor blockers valsartan and losartan improve survival rate clinically and suppress tumor growth via apoptosis related to PI3K/AKT signaling in nasopharyngeal carcinoma

  2021influential citation
• Lung cancer risk and the inhibitors of angiotensin converting enzyme; an updated review on recent evidence

  2021cites this paper
• Cancer risk in dialyzed patients with and without diabetes.

  2020cites this paper
• Risk of lung cancer and renin–angiotensin blockade: a concise review

  2020cites this paper
• Renin-angiotensin system and cancer: epidemiology, cell signaling, genetics and epigenetics

  2020cites this paper
• Renin–angiotensin system inhibitor use and colorectal cancer risk and mortality: A dose–response meta analysis

  2020cites this paper
• Association between Angiotensin-Converting Enzyme Inhibitors and Lung Cancer—A Nationwide, Population-Based, Propensity Score-Matched Cohort Study

  2020cites this paper
• The Therapeutic Potential of Angiotensin-converting Enzyme and Angiotensin Receptor Inhibitors in the Treatment of Colorectal Cancer: Rational Strategies and Recent Progress.

  2019cites this paper
• Systematic review and meta-analysis of randomised controlled clinical trial evidence refutes relationship between pharmacotherapy with angiotensin-receptor blockers and an increased risk of cancer.

  2019cites this paper
• Hepatocyte Growth Factor and Macrophage-Stimulating Protein "Hinge" Analogs to Treat Pancreatic Cancer.

  2019cites this paper
• Retrospective clinical study of renin-angiotensin system blockers in lung cancer patients with hypertension

  2019cites this paper
• Prospects of Pharmacological Interventions to Organismal Aging

  2018cites this paper
• Antihypertensive drug use and breast cancer risk: a meta-analysis of observational studies

  2017cites this paper
• From rapalogs to anti-aging formula

  2017cites this paper
• Involvement of local renin‐angiotensin system in immunosuppression of tumor microenvironment

  2017cites this paper
• Angiotensin receptor blockers and breast cancer risk: a meta-analysis.

  2016cites this paper
• Translating the Science of Aging into Therapeutic Interventions.

  2016cites this paper
• Renin–angiotensin system blockade for the risk of cancer and death

  2016cites this paper
• The Use of Telmisartan and the Incidence of Cancer.

  2016cites this paper
• Strategies and Challenges in Clinical Trials Targeting Human Aging

  2016cites this paper
• Associations between metabolic disorders and risk of cancer in Danish men and women – a nationwide cohort study

  2016cites this paper
• Modulating effect of losartan potassium on the mutagenicity and recombinogenicity of doxorubicin in somatic cells of Drosophila melanogaster.

  2016cites this paper
• Strategies addressing inadequate information on health factors in pharmacoepidemiology studies relying on healthcare databases: commentary from a public workshop

  2016cites this paper
• The Way Forward: Translation

  2016cites this paper
• Syddansk Universitet Associations between metabolic disorders and risk of cancer in Danish men and women a nationwide cohort study

  2016cites this paper
• Aalborg Universitet Associations between metabolic disorders and risk of cancer in Danish men and women a nationwide cohort study

  2016cites this paper
• Type 1 and Type 2 Diabetes and Cancer Mortality in the 2002-2009 Cohort of 39 811 French Dialyzed Patients

  2015cites this paper
• Angiotensins as therapeutic targets beyond heart disease.

  2015cites this paper
• Long term antihypertensive drug use and prostate cancer risk: A 9-year population-based cohort analysis.

  2015cites this paper
• Matrix‐assisted laser desorption/ionisation (MALDI) TOF analysis identifies serum angiotensin II concentrations as a strong predictor of all‐cause and breast cancer (BCa)‐specific mortality following breast surgery

  2015influential citation
• [Oncology-related issues of angiotensin-receptor blockers].

  2015cites this paper
• Original Article Angiotensin receptor blockers (ARBs) reduce the risk of lung cancer: a systematic review and meta-analysis

  2015cites this paper
• Az angiotenzinreceptor-gátlók onkológiai vonatkozásai

  2015cites this paper
• Angiotensin receptor blockers use and the risk of lung cancer: A meta-analysis

  2015cites this paper
• Angiotensin receptor blockers (ARBs) reduce the risk of lung cancer: a systematic review and meta-analysis.

  2015cites this paper
• Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy and colorectal cancer: a systematic review and meta-analysis

  2015cites this paper
• Lack of an Association between Angiotensin Receptor Blocker Based Therapy and Increased Risk of Cancer: Evidence from Large Observational Studies

  2015cites this paper
• Lowered Cancer Risk With ACE Inhibitors/ARBs: A Population‐Based Cohort Study

  2014cites this paper
• Antihypertension and colorectal cancer prevention: getting two birds with one stone?

  2014cites this paper
• The use of angiotensin II receptor antagonists to increase the efficacy of radiotherapy in cancer treatment.

  2014cites this paper
• 6.1.1 UNDERSTANDING DISEASE THROUGH SYSTEMS THINKING

  2014cites this paper
• [Renin-angiotensin system and urological cancers].

  2014cites this paper
• ACE Inhibitors and ARBs: Do They Reduce the Risk of Cancer?

  2014cites this paper
• Koschei the immortal and anti-aging drugs

  2014cites this paper
• Drug development: how academia, industry and authorities interact

  2014cites this paper
• Genotoxic evaluation of five Angiotesin II receptor blockers: in vivo and in vitro micronucleus assay.

  2014cites this paper
• Angiotensin II drives the production of tumor-promoting macrophages.

  2013cites this paper
• Angiotensin II-induced hypertension dose-dependently leads to oxidative stress and DNA damage in mouse kidneys and hearts

  2013cites this paper
• Cancer in cardiovascular drug trials and vice versa: a personal perspective.

  2013cites this paper
• Angiotensin receptor blockers: are they related to lung cancer?

  2013cites this paper
• Long-term use of angiotensin II receptor blockers and risk of cancer: a population-based cohort analysis.

  2013cites this paper
• Angiotensin-receptor blockers and risk of Alzheimer's disease in hypertension population--a nationwide cohort study.

  2013cites this paper
• The renin-angiotensin system as a target of novel anticancer therapy.

  2013cites this paper
• Increased risk of gastrointestinal malignancy in patients with diabetes mellitus and correlations with anti-diabetes drugs: a nationwide population-based study in Taiwan.

  2013cites this paper
• An evaluation of the latest evidence relating to renin–angiotensin system inhibitors

  2013cites this paper
• Remote control of macrophage production by cancer

  2013cites this paper
• Angiotensin and systems thinking: wrapping your mind around the big picture.

  2013cites this paper
• The risk of malignant neoplasms development at the intake of different classes of antihypertensive drugs

  2013cites this paper
• Récepteurs de type 1 à l’angiotensine-2 (AT1R) et cancers

  2013cites this paper
• [Angiotensin-2 type 1 receptors (AT1R) and cancers].

  2013cites this paper
• Gastroesophageal Reflux Disease and Atrial Fibrillation: A Nationwide Population-Based Study

  2012cites this paper
• Association of Hypertension and Anti-Hypertensive Therapy with Cancers

  2012cites this paper
• The Endothelium, Cardiovascular Disease, and Therapy

  2012cites this paper
• Answering the ultimate question “What is the Proximal Cause of Aging?”

  2012cites this paper
• Антигипертензивная терапия антагонистами рецепторов ангиотензина II и риск развития злокачественных новообразований

  2012cites this paper
• Para: Profesionales Sanitarios De: MAGÍSTER ERIC CONTE Director Nacional de Farmacia y Drogas NOTA INFORMATIVA ANTAGONISTAS DE LOS RECEPTORES DE ANGIOTENSINA II (ARA II), LOS DATOS DISPONIBLES NO APOYAN SU ASOCIACIÓN CON EL RIESGO DE CÁNCER

  2012cites this paper
• Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database

  2012cites this paper
• GPCRs and cancer

  2012cites this paper
• Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions

  2012cites this paper
• Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review

  2012cites this paper
• Increased risk of ischemic stroke in patients with systemic lupus erythematosus: a nationwide population-based study.

  2012cites this paper
• Long-Term Use of Angiotensin Receptor Blockers and the Risk of Cancer

  2012cites this paper
• Candesartan-based therapy and risk of cancer in patients with systemic hypertension (Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] substudy).

  2012cites this paper
• Oral alendronate use and risk of cancer in postmenopausal women with osteoporosis: A nationwide study

  2012cites this paper
• Immortal person time bias in pharmacoepidemiological studies of antihypertensive drugs.

  2011cites this paper
• Cardiovascular medications and risk of cancer.

  2011cites this paper
• Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study.

  2011influential citation
• Statin use and hospitalization in patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study in Taiwan.

  2011cites this paper
• NCI's provocative questions on cancer: some answers to ignite discussion

  2011cites this paper
• Vascular Health and Risk Management Dovepress a Current Evaluation of the Safety of Angiotensin Receptor Blockers and Direct Renin Inhibitors

  year unknowncites this paper